NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

InspireMD, Inc. (NSPR) Stock Analysis

InspireMD, Inc. (NSPR) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NSPR

$0.45

+$0.01 (+2.19%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NSPR with… →

NSPR Key Statistics

As of Oct 21, 2026
Trading
Open
$0.43
Previous Close
$0.44
Day's Range
0.43–0.47
52-Week Range
0.43–2.41
Volume
850.66K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.83
Valuation
Market Cap
$20.83M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.92
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
$8.98M+28.11%
Net Income (FY)
−$48.79M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
46.49M
1-Year Return
−80.93%
Dividend and dates
Earnings Date
November 10, 2026
Avg Volume
89.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NSPR closed at $0.45, −80.93% over 1 year.

InspireMD, Inc. (NSPR) has a market capitalization of $20.83M.

In fiscal 2025, NSPR reported revenue of $8.98M.

NSPR Stock Return by Calendar Year

InspireMD, Inc. (NSPR) 10-year return: what $10,000 became

1 year
$10,000 $1,907
−80.93%
5 years
$10,000 $1,072
−89.28%
10 years
$10,000 $0.09
−99.999%

If you had invested $10,000 in InspireMD, Inc. (NSPR) 10 years ago, at the close on October 21, 2016, it would have been worth $0.09 at the close on October 21, 2026: −99.999% in total, −68.54% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−74.83%
2025−32.32%
2024−6.41%
2023+226.74%
2022−71.52%
2021−40.78%
2020−68.52%
2019−86.50%
2018−96.48%
2017−94.80%
2016 (partial year)−47.37%

As of October 21, 2026.

NSPR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$8.98M−$48.79M−543.3%
2024$7.01M−$32.01M−456.6%
2023$6.21M−$19.92M−321.0%
2022$5.17M−$18.49M−357.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$8.98M$2.65M−$49.61M−$48.79M−543.3%
2024$7.01M$1.51M−$33.50M−$32.01M−456.6%
2023$6.21M$1.81M−$21.14M−$19.92M−321.0%
2022$5.17M$1.12M−$18.71M−$18.49M−357.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NSPR Valuation vs Medical Devices Median

Median of 145 stocks
MetricNSPRMedical Devices medianvs median
P/S ratio1.922.5324% below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

InspireMD, Inc. (NSPR) carries a market capitalisation of $20.83M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 127 employees.

NSPR last closed at $0.45 on October 21, 2026. That is +$0.01 (+2.19%) against the previous close. Over the past 52 weeks the price has ranged from $0.43 to $2.41. The latest close sits 5.34% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $8.98M. Against the prior fiscal year total of $7.01M, that is a change of +28.11%. The same year closed with a net loss of $48.79M. Earnings per share on a trailing basis come to −0.62.

Across the 4 fiscal years on file, revenue moves from $5.17M in 2022 to $8.98M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1.92. On price-to-sales that is 24.04% below the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

The trailing one-year total return is −80.93%. Measured over 10 years, that is −68.54% a year compounded. Beta against the wider market is reported at 0.83. Daily returns over the trailing 10 years annualize to a volatility of 112.13%.

Growth & Income

The record shows no dividend for NSPR.

So far in 2026 the total return is −74.83%. Across the complete calendar years on file, 2023 returned +226.74% and 2018 returned −96.48%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

InspireMD, Inc. (NSPR) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
InspireMD, Inc. NSPR $20.83M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. InspireMD, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About InspireMD, Inc.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.

Visit website →